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This communication reviews recent literature and summarizes hepatobiliary abnormalities that may complicate the clinical course
of celiac disease. A wide spectrum of hepatobiliary diseases has been described, including asymptomatic elevations of liver enzyme
levels, nonspeciﬁc hepatitis, nonalcoholic fatty liver disease, and autoimmune and cholestatic liver disease. Moreover, in the
majority of patients, liver enzyme levels will normalize on a gluten-free diet. In addition, celiac disease may be associated with
rare hepatic complications, such as hepatic T-cell lymphoma. Because many celiac patients do not have overt gastrointestinal
symptoms, a high index of suspicion is required. Simple methods of detecting celiac disease such as serum antibody tests help in
the early identiﬁcation of the disease, thus preventing serious complications of the disorder. The IgG DGP antibody test and IgA
tTG antibody test used in combination are an excellent screening test for suspected cases of celiac disease.
1.Introduction
Celiac disease (CD), or gluten-sensitive enteropathy (GSE),
is an autoimmune disorder characterized by reversible small
bowel mucosal inﬂammation with villous atrophy aﬀecting
patients with a speciﬁc genetic predisposition (HLA DR3-
DQ2 and HLA DR4-DQ8). The mucosal lesion develops
after ingestion of dietary gluten and recovers when gluten-
containing cereals, wheat, rye, and barley, are withdrawn
from the diet [1]. In untreated CD, the characteristic
abnormalities in the small bowel mucosa are villous atrophy,
crypt hyperplasia, and an increased density of inﬂammatory
cells in the epithelium and lamina propria [2–4]. The
small bowel lesion of CD is a dynamic process whereby
mucosal damage to the small intestine develops in three
subsequent phases: (a) inﬁltrative phase, characterized solely
by an increased number of intraepithelial lymphocytes; (b)
hyperplastic phase, characterized by crypt hypertrophy; (c)
destructive phase, which is characterized by progressive
villous atrophy ultimately leading to the ﬂattening of the
mucosa [5].
Abnormal immune response to gliadin, genetic, and
environmental factors plays a role in the pathogenesis of CD.
Infectious agents have been implicated in the pathogenesis
of many autoimmune disorders. Transient infections or
increased permeability of the mucosa may facilitate disease
onset induced by the uptake of gluten peptides into a
microenvironmental milieu in the small intestinal mucosa
[6]. An environmental factor, such as an infectious agent,
is thought to precipitate the disease via various pathogenic
mechanisms, such as molecular mimicry, resulting in mod-
ulation of the host’s immune tolerance [7]. Recently, two
patients with onset of CD after resolution of acute hepatitis
B virus (HBV) infection have been reported in the literature
[6]. Celiac disease has also been described in association
with hepatitis C virus (HCV), rotavirus, adenovirus 12,
and astrovirus as another immunologic manifestation of
this infectious disease [8–11]. On the contrary, Plot et
al. (2009) examined the association between serological
evidence of past infection with Toxoplasma gondii,r u b e l l a
virus, cytomegalovirus, Treponema pallidum, and Epstein-
Barr virus and the coexistence of CD. The results implied2 International Journal of Hepatology
that certain infections may generate an immunological
environment that disfavours future appearance of certain
autoimmune conditions such as CD [12]. Hence, under-
standing the relationship between infectious agents and
autoimmune disorders is of importance that may assist in
prediction, early diagnosis, and perhaps also the prevention
of CD [7].
Population-based screening studies have shown that CD
is very common and aﬀects about one in 120 [13]. The
diagnosis of CD is easily overlooked as patients can present
with mild or atypical symptoms or the condition can even be
clinically silent. Patients may present with only subtle, if any,
symptoms [14], which is the main reason why the disease
is highly underdiagnosed in India and elsewhere. In recent
years, recognition of CD has been substantively improved
with increasing awareness for CD amongst health care pro-
fessionals and partly as a result of more modern serological
assays for screening. The advent of serological methods
for the detection of antibodies to gliadin, endomysial, and
tissue transglutaminase has enabled large-scale screening for
CD, thus preventing serious complications of the disorder.
The most common serological tests for the screening of
CD are the indirect immunoﬂuorescence (IFA) method of
detecting endomysial antibodies (EmA) and ELISA methods
of detecting antibodies to tissue transglutaminase (tTG)
and gliadin [15, 16]. Because of the limited sensitivity and
speciﬁcity of gliadin antibody assays, use of this method is
more limited than EmA and tTG. Reliance on EmA and tTG
immunoassays,however,mayallowcasesofIgA-deﬁcientCD
to go undetected [17]. Both immunoassays may be of limited
utility detecting IgG antibodies. IgG gliadin antibody tests
are useful in establishing diagnosis of CD in IgA deﬁcient
patients.Morerecently,anewgenerationofpromisingassays
detecting the presence of deamidated synthetic peptides of
gliadin (DGP) has shown very high diagnostic performance
equivalent to conventional tests [18, 19]. The IgG DGP and
IgA tTG in combination are an excellent screening algorithm
for suspected cases of CD [19].
Although most symptomatic patients have symptoms
related to the gastrointestinal tract, many extraintestinal
manifestations have been described. The target organs
include endocrine system [20–22], kidney [23, 24], skin
[25], nervous system [26], and reproductive systems [27].
A number of hepatobiliary tract and pancreatic disorders
have also been documented in patients with CD [28].
Some of these have been hypothesized to share common
genetic factors or have a common immunopathogenesis,
such as primary biliary cirrhosis (PBC), primary sclerosing
cholangitis (PSC), and autoimmune forms of hepatitis or
cholangitis [28]. Other hepatic changes in CD that may
be associated with increased intestinal permeability could
result in translocation of gut bacteria, kupﬀer cell stimu-
lation, and production of tumor necrosis factor-α (TNF-
α), proinﬂammatory cytokine, and reactive oxygen species,
resulting in nonalcoholic steatohepatitis (NASH). It is also
hypothesized that the malnutrition in CD might lead to
chronic deﬁciency of a lipotropic factor (e.g., choline), with
an associated pyridoxine deﬁciency, resulting in hepatic
steatosis [29]. In addition, CD may be associated with rare
hepatic complications, such as hepatic T-cell lymphoma
[28]. Finally, pancreatic abnormalities may be caused by CD
orcoexistwithCD.Bothendocrineandexocrinefunctionsof
the pancreas may be substantially changed in CD. We review
the literature pertaining to hepatobiliary abnormalities that
may be seen in association with celiac disease.
2. HepatobiliaryDisorders
Hepatic changes in patients with CD were initially described
by Pollock in 1977 [30]. Since then the relationship between
hepatobiliary dysfunction and CD is well established,
ranging from asymptomatic or cryptogenic hypertransam-
inasemia to chronic liver disease (CLD) [31]. Thus, the
hepatologist needs to consider CD in the diﬀerential of
abnormal liver blood tests and to be aware of the clinical
implications of this frequent disease in patients with liver
disorders. The etiology is varying and multifactorial, such as
genetic predisposition, precocity, and duration of exposure
to gluten that may inﬂuence reversibility of liver damage
[32].
2.1. Asymptomatic Elevations of Liver Enzyme Levels.
Transaminases (ALT (alanine aminotransferase) and AST
(aspartate aminotransferase)), γ-glutamyl transpeptidase (γ-
GT), and alkaline phosphatase (ALP) are classically termed
as liver enzymes; however, they can be found in almost
every organ. Elevated levels of the transaminases ALT and
AST are signs of disturbed permeability of the cells, in
which these enzymes can be found. In contrast to ALT,
which is mainly liver speciﬁc, the AST is found in other
organs as well, for example, heart and skeletal muscle [33].
As such hypertransaminasemia has been observed in up
to 40% of untreated celiac patients [34]. Celiac disease
at diagnosis may present in 5%–10% of patients as an
asymptomatic or cryptogenic hypertransaminasemia, as an
expression of a mild liver dysfunction with a histological
picture of nonspeciﬁc reactive hepatitis (celiac hepatitis)
which frequently disappears after gluten suppression [32,
35–37]. At a mild elevation of liver enzymes, reevaluation
is recommended; however, if an elevation persists and is
suspicious for a liver disease, a speciﬁc workup is necessary
[33].
2.2.NonalcoholicFattyLiverDisease. Nonalcoholicfattyliver
disease (NAFLD) refers to a spectrum of diseases of the
liver ranging from simple steatosis (i.e., fatty inﬁltration of
the liver) to nonalcoholic steatohepatitis (i.e., steatosis with
inﬂammation and hepatocyte necrosis (NASH)) to cirrhosis.
Nonalcoholic fatty liver disease is the most common cause
of elevated liver enzymes in adults and the most common
cause of cryptogenic cirrhosis, which is cirrhosis that cannot
be explained by hepatitis, alcohol abuse, toxin exposure,
autoimmune disease, congenital liver disease, vascular out-
ﬂow obstruction, or biliary tract disease [38].
Celiacdiseasehasbeenreportedin4%–13%ofcaseswith
NASH [39–41]. The etiopathogenesis of hepatic steatosis in
CD is uncertain. It has been suggested that malabsorption inInternational Journal of Hepatology 3
CD might lead to chronic deﬁciency of a lipotropic factor
(e.g., choline), with an associated pyridoxine deﬁciency,
and hepatic steatosis might occur [29]. It is plausible
that CD, like small intestinal bacterial overgrowth (SIBO),
can be associated with increased intestinal permeability
[42]. The increased intestinal permeability could result in
translocation of gut bacteria, kupﬀer cell stimulation, and
production of tumor necrosis factor-α (TNF-α), proinﬂam-
matory cytokine, and reactive oxygen species, resulting in
NASH. Further studies are warranted to deﬁne the precise
pathogenetic mechanism or mechanisms for NAFLD in CD.
2.3. Autoimmune Hepatobiliary Disorders. Autoimmune
hepatobiliary disorders are frequently associated with CD,
but they might remain undiagnosed because of lack of
symptoms, absence of liver-speciﬁc autoantibodies, or mis-
diagnosis of celiac hepatitis. Acute hepatitis in celiac patients
should induce one to suspect an autoimmune origin [43].
Patients with end-stage autoimmune liver disease, especially
those who are HLA-DQ2 or HLA-DQ8 positive, had a
high prevalence of CD-associated antibodies [44]. Indeed,
CD has been found in 3%–7% of patients with PBC, in
3%–6% with autoimmune hepatitis (AIH), and in 2%-
3% with PSC. Diﬀerently from cryptogenic liver injury,
autoimmune liver dysfunction, found in CD, does not
usually improve after a gluten-free diet (GFD) [35]. Since
CD is common among patients with autoimmune liver
disease, screening autoimmune liver disease patients for CD
is indicated. Although the magnitude of beneﬁt from a GFD
in reversing autoimmune liver disease in patients with CD is
controversial, it may reduce the risk of further complications
of CD [45].
2.3.1. Autoimmune Hepatitis and Cholangitis. Although AIH
has been reported in only a limited number of case reports
and population-based studies, the prevalenceof CD has been
found in 3%–6% with AIH [35, 45]. Conversely, patients
with CD have a sixfold greater risk of AIH compared to
the general population [46]. The two forms of AIH with
diﬀerent serological and clinical features can be found in
association with CD. Indeed, the two well-deﬁned forms of
AIH, found in CD, are AIH type 1, which is characterized by
positivity for ANA/SMA and aﬀects much more frequently
adult patients, and AIH type 2, characterized by LKM and/or
LC1 antibody positivity, usually conﬁned to childhood CD
[47, 48]. Seronegative AIH has also been reported with
CD [49]. In CD with AIH, GFD plus immunosuppressants
determines a high remission rate. When clinical remission is
reached, a prolonged immunosuppressive regimen induces
a high sustained remission rate after treatment withdrawal
[50].
Autoimmune cholangitis (antimitochondrial antibody-
negative PBC) is a rare chronic cholestatic liver disease.
CD should be considered in all patients diagnosed with
autoimmune cholangitis as a GFD may avoid the need for
immunosuppressive therapy in aﬀected patients [51].
2.3.2. Primary Sclerosing Cholangitis. An association be-
tween CD and PSC was ﬁrst described in1988 by Hay et al.
in a report of three patients with PSC later diagnosed with
CD [52]. Thereafter, few other cases were reported [53, 54].
It has been diﬃcult to show good evidence for a response of
the PSC to a gluten-free diet.
2.3.3.PrimaryBiliaryCirrhosis. TheassociationbetweenCD
and PBC was ﬁrst described in four patients by Logan
et al. [55]. Numerous case reports followed formal epi-
demiological studies to determine the prevalence of PBC in
patientswithCD[56].AlthoughanassociationbetweenPBC
and CD has been reported, there are still conﬂicting data
concerning this issue [57]. Considering the malabsorption,
weight loss and osteoporosis are clinical manifestations
common to both entities, screening for CD in PBC and vice
versa, for antimitochondrial antibodies are advisable in adult
CD patients for early diagnosis and institution of speciﬁc
therapeutic measures [57].
2.4. Miscellaneous Hepatobiliary Disorders in Celiac Disease.
Celiac disease can present great clinical heterogeneity. Its
association with a series of intestinal and nonintestinal
diseases, whether immunologically mediated or otherwise,
presents a higher than normal frequency. Celiac disease
has increasingly been reported with a variety of other liver
diseases.
2.4.1. Hemochromatosis. Celiac disease and hereditary
hemochromatosis (HH) are genetic disorders with opposite
eﬀects on iron absorption and probably on the absorption of
someotherdivalentmetalsincludingcopper[58].Hereditary
hemochromatosis is the most common autosomal recessive
disease in the Caucasian population and is characterised
by an iron overload state. Celiac disease, or GSE, on the
other hand is frequently associated with iron deﬁciency
anemia. The concomitant presence of HH and CD is rare,
and susceptibility to both is associated with genes in the
major histocompatibility complex (MHC) on the short arm
of chromosome 6 [59, 60]. However, their MHC association
is quite distinct. CD is associated with the HLA-DQ2 allele
as well as non-HLA genes, whereas HH is associated with
the HLA-A3 and B7 alleles of the MHC region [61]. It is not
clear whether there is a genetic relationship between the two
conditions or their association merely coincidence based on
their higher frequencies in the general population. ¡?ehlt?¿
Occult CD may compensate for increased divalent-
metal transporter 1 (DMT1) expression in a speciﬁc subset
of individuals with homozygous C282Y mutations in the
hemochromatosis (HFE) gene, thus contributing to the low
penetrance of HH [62]. On the other hand, HFE mutations
do not constitute a protective factor against the development
of iron deﬁciency, which seems to be mainly determined by
the severity of the intestinal lesions [63].
2.4.2. Gallstone Diseases. Impaired gallbladder motility has
been reported also in patients with CD in relation to
reduced secretion of enteric hormones and/or decreased
gallbladder sensitivity to them. In particular, untreated celi-
acs showed low postprandial cholecystokinin and increased4 International Journal of Hepatology
fasting somatostatin levels [64]. In spite of these physiolog-
ical alterations, there does not appear to be a signiﬁcant
predisposition to gallstones in CD except for elderly celiac
[65].
2.4.3. Hepatic Vein Obstruction. The association of Budd-
Chiari syndrome (BCS) and CD is rare and deﬁned by
obstruction of the hepatic vein. All but one of the reported
cases had thrombosis of hepatic veins, and one patient had
membranous obstruction of inferior vena cava (IVC) [66–
68]. Celiac disease should be considered especially in the
event of BCS and malabsorption. The long-term outcome
is favorable with a GFD and antivitamin K treatment [69].
A percutaneous balloon angioplasty was performed, with
s a t i s f a c t o r yo u t c o m ei nc a s eo fm e m b r a n o u so b s t r u c t i o no f
the inferior vena cava [68].
2.4.4. Noncirrhotic Portal Hypertension. Nodular regener-
ative hyperplasia (NRH) of the liver is a rare disorder
that is characterized by a nodular transformation of the
hepatic parenchyma without ﬁbrous septa between the
nodules, is often associated with connective tissue disorders,
hematological malignancy, or drugs, and is a cause of
noncirrhotic portal hypertension [70, 71]. Antiphospholipid
antibodies (aPL) are a heterogeneous group of circulating
autoantibodies including anticardiolipins found in the sera
of healthy subjects and patients with autoimmune and infec-
tious diseases. IgA anticardiolipin antibodies were reported
recently in celiac patients with NRH [72, 73].
Idiopathic portal hypertension (IPH) or noncirrhotic
portal ﬁbrosis (NCPF) is a disorder generally classiﬁed
as a noncirrhotic portal hypertension of unknown etiol-
ogy and is clinically characterized by portal hypertension,
splenomegaly, and pancytopenia [74, 75]. Idiopathic portal
hypertension is a heterogeneous and multifactorial disorder
with a potential genetic contribution, seen most often in the
Indian subcontinent and in East Asia [76]. The association
of CD with IPH has been recently reported in the literature
[77, 78]. The improvement of portal hypertension with
a GFD implicates a causal relationship between portal
hypertension and increased inﬂammatory reactions in CD
[79]. The coexistence of CD and IPH suggests that there
may be an immunological link between these two conditions
[78]. Therefore, the testing for CD in patients with IPH is
warranted.
2.4.5. Hepatic Malignancies. Celiac disease is associated with
intestinal lymphoma and other forms of cancer, especially
adenocarcinoma of the small intestine, of the pharynx, and
of the esophagus. Enteropathy-associated T-cell lymphoma
(EATL) is a rare form of high-grade, T-cell non-Hodgkin
lymphoma (NHL) of the upper small intestine that is speciﬁ-
cally associated with CD. Enteropathy-associated T-cell lym-
phoma derives from a clonal proliferation of intraepithelial
lymphocytes (IELs) and is often disseminated at diagnosis.
Extraintestinal presentations are not uncommon in the liver,
spleen, thyroid, skin, nasal sinus, and brain [80]. Lymphoma
in the liver is apparently secondary to intestinal lymphoma,
complicating celiac disease [30]. In general, involvement
of the liver in CD patients with lymphoma is limited and
overshadowed by the clinical course of the intestinal disease.
The outlook of EATL is poor. Hepatocellular carcinoma
(HCC) in one patient and hepatosplenic lymphoma, a rare
type of peripheral T-cell lymphoma with rearrangement of
the γδT-cell receptor, have been reported [30, 81, 82].
2.4.6. End-Stage Liver Disease. Although rare, severe hepatic
damage or failure can develop in association with CD [31].
In a few cases, when CD is diagnosed, a more severe liver
injury, characterized by a cryptogenic chronic hepatitis or
liver cirrhosis, was present [35]. Celiac disease is up to 10
times more frequent among patients with CLD [83]. Severe
liver failure and decompensated cryptogenic liver cirrhosis
are potentially treatable with institution of a GFD. Dietary
treatment may prevent progression to hepatic failure, even
in cases in which liver transplantation is considered [84].
Therefore, all patients with cryptogenic cirrhosis should be
screened for CD-related antibodies before proceeding to a
liver transplant.
Increased intestinal permeability, SIBO, kupﬀer cell
abnormalities,directtoxicityofgliadinpeptides,oragliadin-
stimulated immunopathological process may have a role
to play in the progression of CLD among celiac patients
[83, 84]. The patients with CLD have a higher likelihood
of false positive results regarding anti-tTG antibodies, which
is due, in some instances, to increased immunoglobulins
concentrations and, in most individuals, to the role of trans-
glutaminaseinliverﬁbrosismechanisms[85].Thespeciﬁcity
and sensitivity of tTG assays have been questioned, and
several publications describe positive tTG antibody results in
autoimmune diseases other than CD, while the samples are
negative for EmA [86–88]. Furthermore, the ﬁnding of false
positive results for anti-tTG antibodies is a relevant problem
forantibodies toguineapigtTG,whereasthenumberoffalse
positives is far much lower for antibodies to recombinant
human tTG, the usually routine test for CD screening. More
recently, a new generation of promising assays detecting the
presence of deamidated synthetic peptides of gliadin (DGP)
has shown very high diagnostic performance equivalent to
conventional tests [18, 19]. The combination of two assays
makes diagnostic accuracy higher. Therefore, a serologic
screening by combining tTG IgA with DGP IgG or EmA
testingcouldbeconsideredasthebestinitialtestforCD[19].
3. Conclusions
Inconclusion,anumberofhepatobiliarydisordershavebeen
documented in patients with celiac disease. Consequently,
newly onset celiac disease should be rigorously checked for
asymptomatic hepatic damage and conversely, any crypto-
genic liver disorder, including end-stage liver disease, should
be investigated for celiac disease. Presently, it is diﬃcult to
establish if the two main kinds of hepatic injury (cryptogenic
and autoimmune) found in celiac disease are discrete entities
with a diﬀerent pathogenesis or if they are an expression of
the same disorder, where genetic factors and the duration of
gluten exposure may determine the severity and the patternInternational Journal of Hepatology 5
of hepatic injury. Several communications of isolated cases
of rare hepatobiliary diseases, which probably, only reﬂect a
fortuitous association with celiac disease, have been cited in
the literature.
References
[1] J. S. Trier, “Medical progress: celiac sprue,” New England
Journal of Medicine, vol. 325, no. 24, pp. 1709–1719, 1991.
[2] K. K. Prasad, B. R. Thapa, C. K. Nain, A. K. Sharma,
and K. Singh, “Brush border enzyme activities in relation
to histological lesion in pediatric celiac disease,” Journal of
Gastroenterology and Hepatology, vol.23,no.8,pp.e348–e352,
2008.
[3] K. K. Prasad, B. R. Thapa, C. K. Nain, and K. Singh,
“Assessmentofthediagnosticvalueofduodenalbulbhistology
in patients with celiac disease, using multiple biopsy sites,”
JournalofClinicalGastroenterology,vol.43,no.4,pp.307–311,
2009.
[4] K. K. Prasad, B. R. Thapa, C. K. Nain, and K. Singh,
“Assessment of histologic lesion variability of the duodenal
mucosa in children with celiac disease,” World Journal of
Pediatrics, vol. 6, pp. 60–64, 2010.
[5] M. N. Marsh, “Grains of truth: evolutionary changes in
small intestinal mucosa in response to environmental antigen
challenge,” Gut, vol. 31, no. 1, pp. 111–114, 1990.
[6] S. Soto Iglesias, S. V´ azquez Rodr´ ıguez, J. L. Ulla Rocha et
al., “Onset of celiac disease after acute hepatitis B infection,”
GastroenterologiayHepatologia,vol.33,no.1,pp.17–20,2010.
[7] L. Plot and H. Amital, “Infectious associations of Celiac
disease,” Autoimmunity Reviews, vol. 8, no. 4, pp. 316–319,
2009.
[8] I. Aguancha, J. M. Valera, C. Hurtado, G. Smok, and J.
Brahm, “Chronic hepatitis C and celiac sprue: an infrequent
association,”GastroenterologiayHepatologia,v ol.27,no .7,pp .
408–410, 2004.
[ 9 ]L .C .S t e n e ,M .C .H o n e y m a n ,E .J .H o ﬀenberg et al.,
“Rotavirus infection frequency and risk of celiac disease
autoimmunity in early childhood: a longitudinal study,”
American Journal of Gastroenterology, vol. 101, no. 10, pp.
2333–2340, 2006.
[10] M. Lawler, P. Humphries, C. O’Farrelly et al., “Adenovirus 12
E 1 Ag e n ed e t e c t i o nb yp o l y m e r a s ec h a i nr e a c t i o ni nb o t ht h e
normal and coeliac duodenum,” Gut, vol. 35, no. 9, pp. 1226–
1232, 1994.
[11] S.L.Smits,M.VanLeeuwen,A.A.VanDerEijketal.,“Human
astrovirusinfectioninapatientwithnew-onsetceliacdisease,”
Journal of Clinical Microbiology, vol. 48, no. 9, pp. 3416–3418,
2010.
[12] L. Plot, H. Amital, O. Barzilai, M. Ram, B. Nicola, and
Y. Shoenfeld, “Infections may have a protective role in the
etiopathogenesis of celiac disease,” Annals of the New York
Academy of Sciences, vol. 1173, pp. 670–674, 2009.
[13] S. Lal, C. K. Nain, K. K. Prasad, and B. R. Thapa, “Celiac
disease in Chandigarh: a population survey,” Indian Journal of
Gastroenterology, vol. 24, supplement 1, p. A39, 2005.
[14] G. R. Corazza, M. Frisoni, E. A. Treggiari et al., “Subclinical
celiac sprue: increasing occurrence and clues to its diagnosis,”
Journal of Clinical Gastroenterology, vol. 16, no. 1, pp. 16–21,
1993.
[ 1 5 ]T .P .C h o r z e l s k i ,E .H .B e u t n e r ,a n dJ .S u l e j ,“ I g Aa n t i -
endomysium antibody. A new immunological marker of
dermatitis herpetiformis and coeliac disease,” British Journal
of Dermatology, vol. 111, no. 4, pp. 395–402, 1984.
[16] D. Schuppan and E. G. Hahn, “IgA anti-tissue transglutami-
nase: setting the stage for coeliac disease screening,” European
Journal of Gastroenterology and Hepatology, vol. 13, no. 6, pp.
635–637, 2001.
[17] A. Pacht, N. Sinai, L. Hornstein, V. Kumar, N. Ish-Shalom,
and A. Lerner, “The diagnostic reliability of anti-endomysial
antibody in celiac disease: the north Israel experience,” Israel
Journal of Medical Sciences, vol. 31, no. 4, pp. 218–220, 1995.
[18] S. Niveloni, E. Sugai, A. Cabanne et al., “Antibodies against
synthetic deamidated gliadin peptides as predictors of celiac
disease: prospective assessment in an adult population with a
high pretest probability of disease,” Clinical Chemistry, vol. 53,
no. 12, pp. 2186–2192, 2007.
[19] E. Sugai, M. L. Moreno, H. J. Hwang et al., “Celiac disease
serology in patients with diﬀerent pretest probabilities: is
biopsy avoidable?” World Journal of Gastroenterology, vol. 16,
no. 25, pp. 3144–3152, 2010.
[20] P.Collin,K.Kaukinen,M.V¨ alim¨ aki,andJ.Salmi,“Endocrino-
logical disorders and celiac disease,” Endocrine Reviews, vol.
23, no. 4, pp. 464–483, 2002.
[ 2 1 ]E .F e r r a n t e ,C .G i a v o l i ,L .E l l ie ta l . ,“ E v a l u a t i o no fG H - I G F -
I axis in adult patients with coeliac disease,” Hormone and
Metabolic Research, vol. 42, no. 1, pp. 45–49, 2010.
[22] M. Delvecchio, A. De Bellis, R. Francavilla et al., “Anti-
pituitary antibodies in children with newly diagnosed celiac
disease: a novel ﬁnding contributing to linear-growth impair-
ment,” American Journal of Gastroenterology, vol. 105, no. 3,
pp. 691–696, 2010.
[23] K. D. Jhaveri, V. D. D’Agati, R. Pursell, and D. Serur, “Coeliac
sprue-associated membranoproliferative glomerulonephritis
(MPGN),”NephrologyDialysisTransplantation,vol.24,no.11,
pp. 3545–3548, 2009.
[24] H. K. Smerud, B. Fellstr¨ o m ,R .H ¨ allgren, S. Osagie, P. Venge,
and G. Kristj´ ansson, “Gluten sensitivity in patients with IgA
nephropathy,”NephrologyDialysisTransplantation,vol.24,no.
8, pp. 2476–2481, 2009.
[25] F. Zingone, C. Bucci, R. Tortora et al., “Body mass index and
prevalence of skin diseases in adults with untreated coeliac
disease,” Digestion, vol. 80, no. 1, pp. 18–24, 2009.
[26] H. J. Freeman, “Neurological disorders in adult celiac disease,”
Canadian Journal of Gastroenterology, vol. 22, no. 11, pp. 909–
911, 2008.
[27] K. K. Prasad, S. Siwatch, S. K. Sinha, C. K. Nain, and K. Singh,
“Celiacdiseaseandreproductivedisorders:associationisoften
neglected,” Gastroenterology Today, vol. 11, pp. 50–54, 2007.
[28] H. J. Freeman, “Hepatobiliary and pancreatic disorders in
celiac disease,” World Journal of Gastroenterology, vol. 12, no.
10, pp. 1503–1508, 2006.
[29] J. E. Naschitz, D. Yeshurun, E. Zuckerman, E. Arad, and J.
H. Boss, “Massive hepatic steatosis complicating adult celiac
disease: report of a case and review of the literature,” American
Journal of Gastroenterology, vol. 82, no. 11, pp. 1186–1189,
1987.
[30] D. J. Pollock, “The liver in coeliac disease,” Histopathology, vol.
1, no. 6, pp. 421–430, 1977.
[31] T. H. Casswall, N. Papadogiannakis, S. Ghazi, and A. N´ emeth,
“Severe liver damage associated with celiac disease: ﬁndings
in six toddler-aged girls,” European Journal of Gastroenterology
and Hepatology, vol. 21, no. 4, pp. 452–459, 2009.
[32] M. D. Cantarero Vallejo, J. G´ omez Camarero, L. Mench´ en, J.
A. Pajares D´ ıaz, and O. Lo Iacono, “Liver damage and celiac6 International Journal of Hepatology
disease,” Revista Espanola de Enfermedades Digestivas, vol. 99,
no. 11, pp. 648–652, 2007.
[33] P.M.LepperandJ.-F.Dufour,“Elevatedtransaminases—what
to do if everything was done?” Praxis, vol. 98, no. 6, pp. 330–
334, 2009.
[34] A. B. Villares, J. A. M. Monteagudo, R. M. Borque, and R. M.
Otero, “Hepatic involvement in celiac disease,” Gastroenterolo-
gia y Hepatologia, vol. 31, no. 1, pp. 25–28, 2008.
[35] U. Volta, “Pathogenesis and clinical signiﬁcance of liver injury
in celiac disease,” Clinical Reviews in Allergy and Immunology,
vol. 36, no. 1, pp. 62–70, 2009.
[36] A. Rubio-Tapia and J. A. Murray, “The liver in celiac disease,”
Hepatology, vol. 46, no. 5, pp. 1650–1658, 2007.
[37] G. Maggiore and S. Caprai, “Liver involvement in celiac
disease,” Indian Journal of Pediatrics, vol. 73, no. 9, pp. 809–
811, 2006.
[38] M. Bayard, J. Holt, and E. Boroughs, “Nonalcoholic fatty liver
disease,” American Family Physician, vol. 73, no. 11, pp. 1961–
1969, 2006.
[39] J. M. Valera, C. Hurtado, J. Poniachik, P. Abumohor, and J.
Brahm, “Study of celiac disease in patients with non-alcoholic
fatty liver and autoimmune hepatic diseases,” Gastroenterolo-
gia y Hepatologia, vol. 31, no. 1, pp. 8–11, 2008.
[40] M. T. Bardella, L. Valenti, C. Pagliari et al., “Searching
for coeliac disease in patients with non-alcoholic fatty liver
disease,” Digestive and Liver Disease, vol. 36, no. 5, pp. 333–
336, 2004.
[41] A. Franzese, M. P. Iannucci, G. Valerio et al., “Atypical
celiac disease presenting as obesity-related liver dysfunction,”
Journal of Pediatric Gastroenterology and Nutrition, vol. 33, no.
3, pp. 329–332, 2001.
[42] L. Miele, V. Valenza, G. La Torre et al., “Increased intestinal
permeability and tight junction alterations in nonalcoholic
fatty liver disease,” Hepatology, vol. 49, no. 6, pp. 1877–1887,
2009.
[ 4 3 ]S .C a p r a i ,P .V a j r o ,A .V e n t u r a ,M .S c i v e r e s ,a n dG .M a g g i o r e ,
“Autoimmune liver disease associated with celiac disease in
childhood: a multicenter study,” Clinical Gastroenterology and
Hepatology, vol. 6, no. 7, pp. 803–806, 2008.
[44] A. Rubio-Tapia, A. S. Abdulkarim, R. H. Wiesner, S. B. Moore,
P. K. Krause, and J. A. Murray, “Celiac disease autoantibodies
in severe autoimmune liver disease and the eﬀect of liver
transplantation,” Liver International, vol. 28, no. 4, pp. 467–
476, 2008.
[45] F. Mirzaagha, S. H. Azali, F. Islami et al., “Coeliac disease
in autoimmune liver disease: a cross-sectional study and a
systematic review,” Digestive and Liver Disease, vol. 42, no. 9,
pp. 620–623, 2010.
[46] J. F. Ludvigsson, P. Elfstr¨ om, U. Broom´ E, A. Ekbom, and S.
M. Montgomery, “Celiac disease and risk of liver disease: a
generalpopulation-basedstudy,”ClinicalGastroenterologyand
Hepatology, vol. 5, no. 1, pp. 63–69.e1, 2007.
[47] D. Villalta, D. Girolami, E. Bidoli et al., “High prevalence
of celiac disease in autoimmune hepatitis detected by anti-
tissue tranglutaminase autoantibodies,” Journal of Clinical
Laboratory Analysis, vol. 19, no. 1, pp. 6–10, 2005.
[48] U. Volta, L. De Franceschi, N. Molinaro et al., “Frequency and
signiﬁcance of anti-gliadin and anti-endomysial antibodies in
autoimmunehepatitis,”DigestiveDiseasesandSciences,vol.43,
no. 10, pp. 2190–2195, 1998.
[49] M. A. Quail, R. K. Russell, C. Bellamy, G. Mieli-Vergani, and
P. M. Gillett, “Seronegative autoimmune hepatitis presenting
after diagnosis of coeliac disease: a case report,” European
Journal of Gastroenterology and Hepatology, vol. 21, no. 5, pp.
576–579, 2009.
[50] A. R. Di Biase, A. Colecchia, E. Scaioli et al., “Autoimmune
liver diseases in a paediatric population with coeliac disease—
a 10-year single-centre experience,” Alimentary Pharmacology
and Therapeutics, vol. 31, no. 2, pp. 253–260, 2010.
[51] R. E. Sedlack, T. C. Smyrk, A. J. Czaja, and J. A. Talwalkar,
“Celiacdisease-associatedautoimmunecholangitis,”American
Journal of Gastroenterology, vol. 97, no. 12, pp. 3196–3198,
2002.
[52] J. E. Hay, R. H. Wiesner, R. G. Shorter, N. F. LaRusso, and W.
P. Baldus, “Primary sclerosing cholangitis and celiac disease. A
novel association,” Annals of Internal Medicine, vol. 109, no. 9,
pp. 713–717, 1988.
[53] U. Volta, L. Rodrigo, A. Granito et al., “Celiac disease in
autoimmune cholestatic liver disorders,” American Journal of
Gastroenterology, vol. 97, no. 10, pp. 2609–2613, 2002.
[54] I. Venturini, R. Cosenza, L. Miglioli et al., “Adult celiac disease
and primary sclerosing cholangitis: two case reports,” Hepato-
Gastroenterology, vol. 45, no. 24, pp. 2344–2347, 1998.
[55] R.F.A.Logan,A.Ferguson,N.D.C.Finlayson,andD.G.Weir,
“Primarybiliarycirrhosisandcoeliacdisease.Anassociation?”
Lancet, vol. 1, no. 8058, pp. 230–233, 1978.
[ 5 6 ]W .D i c k e y ,S .A .M c M i l l a n ,a n dM .E .C a l l e n d e r ,“ H i g h
prevalence of celiac spree among patients with primary biliary
cirrhosis,” Journal of Clinical Gastroenterology,v o l .2 5 ,n o .1 ,
pp. 328–329, 1997.
[57] A. Floreani, C. Betterle, A. Baragiotta et al., “Prevalence of
coeliac disease in primary biliary cirrhosis and of antimito-
chondrial antibodies in adult coeliac disease patients in Italy,”
Digestive and Liver Disease, vol. 34, no. 4, pp. 258–261, 2002.
[58] C. Whittington, “The C282Y mutation may have been posi-
tively selected as it mitigates the infertility of celiac disease,”
Medical Hypotheses, vol. 66, no. 4, pp. 769–772, 2006.
[59] S. Bevan, S. Popat, C. P. Braegger et al., “Contribution of the
MHC region to the familial risk of coeliac disease,” Journal of
Medical Genetics, vol. 36, no. 9, pp. 687–690, 1999.
[60] C. Q. Edwards, M. M. Dadone, M. H. Skolnick, and J. P. Kush-
ner, “Hereditary hemochromatosis,” Clinical Hematology, vol.
11, pp. 411–435, 1982.
[61] J. R. Butterworth, B. T. Cooper, W. M. C. Rosenberg et al.,
“The role of hemochromatosis susceptibility gene mutations
in protecting against iron deﬁciency in celiac disease,” Gas-
troenterology, vol. 123, no. 2, pp. 444–449, 2002.
[62] A. Geier, C. Gartung, I. Theurl et al., “Occult celiac disease
prevents penetrance of hemochromatosis,” World Journal of
Gastroenterology, vol. 11, no. 21, pp. 3323–3326, 2005.
[63] D. Barisani, S. Ceroni, S. Del Bianco, R. Meneveri, and
M. T. Bardella, “Hemochromatosis gene mutations and iron
metabolism in celiac disease,” Haematologica, vol. 89, no. 11,
pp. 1299–1305, 2004.
[64] M.Fraquelli,M.Pagliarulo,A.Colucci,S.Paggi,andD.Conte,
“Gallbladder motility in obesity, diabetes mellitus and coeliac
disease,” Digestive and Liver Disease, vol. 35, no. 3, pp. S12–
S16, 2003.
[65] H. Freeman, M. Lemoyne, and P. Pare, “Coeliac disease,” Best
Practice and Research in Clinical Gastroenterology, vol. 16, no.
1, pp. 37–49, 2002.
[66] F. Ben Hriz, H. Habbassi, N. Maamouri et al., “Budd-Chiari
syndrome associated with celiac disease,” R e v u ed eM e d e c i n e
Interne, vol. 31, no. 2, pp. 160–162, 2010.
[67] R. Kochhar, I. Masoodi, U. Dutta et al., “Celiac disease
and Budd Chiari syndrome: report of a case with review ofInternational Journal of Hepatology 7
literature,” European Journal of Gastroenterology and Hepatol-
ogy, vol. 21, no. 9, pp. 1092–1094, 2009.
[68] F. Mart´ ınez, M. Berenguer, M. Prieto, H. Montes, M. Ray´ on,
and J. Berenguer, “Budd-Chiari syndrome caused by mem-
branous obstruction of the inferior vena cava associated with
coeliac disease,” Digestive and Liver Disease,v o l .3 6 ,n o .2 ,p p .
157–162, 2004.
[69] E. Gelsi, F. Ruitord, M.-C. Saint-Paul, J. Filippi, K. Arab,
and X. H´ ebuterne, “Association of Budd-Chiari syndrome
with a coeliac disease in patient native from North Africa,”
Gastroenterologie Clinique et Biologique, vol. 28, no. 10, pp.
903–905, 2004.
[70] E. Biecker, J. Trebicka, H.-P. Fischer, T. Sauerbruch, and
F. Lammert, “Portal hypertension and nodular regenerative
hyperplasia in a patient with celiac disease,” Zeitschrift fur
Gastroenterologie, vol. 44, no. 5, pp. 395–398, 2006.
[71] F. Tinsa, I. Brini, A. El May, D. Bousnina, K. Boussetta,
and S. Bousnina, “Nodular regenerative hyperplasia of the
liver, coeliac disease and Sjogren’s syndrome in a child,”
Gastroenterologie Clinique et Biologique, vol. 34, no. 1, pp. 40–
42, 2010.
[72] E. L. R. Cancado, D. M. Medeiros, M. M. Deguti et al., “Celiac
disease associated with nodular regenerative hyperplasia, pul-
monary abnormalities, and IgA anticardiolipin antibodies,”
JournalofClinicalGastroenterology,vol.40,no.2,pp.135–139,
2006.
[73] A. Austin, E. Campbell, P. Lane, and E. Elias, “Nodular
regenerative hyperplasia of the liver and coeliac disease:
potential role of IgA anticardiolipin antibody,” Gut, vol. 53,
no. 7, pp. 1032–1034, 2004.
[74] M. Okudaira, M. Ohbu, and K. Okuda, “Idiopathic portal
hypertensionanditspathology,”SeminarsinLiverDisease,vol.
22, no. 1, pp. 59–71, 2002.
[75] K. K. Prasad, “Histopathological changes in liver diseases,” in
Liver: A Complete Book on Hepato-Pancreato-Biliary Diseases,
M. A. Mahtab and S. Rahman, Eds., pp. 69–106, Elsevier,
Chennai, India, 2009.
[76] R. K. Dhiman, Y. Chawla, R. K. Vasishta et al., “Non-cirrhotic
portal ﬁbrosis (idiopathic portal hypertension): experience
with 151 patients and a review of the literature,” Journal of
GastroenterologyandHepatology,vol.17,no.1,pp.6–16,2002.
[77] B. C. Sharma, D. K. Bhasin, and R. Nada, “Association of
celiac disease with non-cirrhotic portal ﬁbrosis,” Journal of
Gastroenterology and Hepatology, vol. 21, no. 1, pp. 332–334,
2006.
[78] F. Zamani, A. Amiri, R. Shakeri, A. Zare, and M. Mohamad-
nejad, “Celiac disease as a potential cause of idiopathic portal
hypertension: a case report,” Journal of Medical Case Reports,
vol. 3, article no. 68, 2009.
[79] B. Kara and M. Sandikci, “Successful treatment of portal
hypertension and hypoparathyroidism with a gluten-free
diet,” Journal of Clinical Gastroenterology,v o l .4 1 ,n o .7 ,p p .
724–725, 2007.
[80] C. Catassi, I. Bearzi, and G. K. T. Holmes, “Association of
celiac disease and intestinal lymphomas and other cancers,”
Gastroenterology, vol. 128, no. 4, pp. S79–S86, 2005.
[81] N. L. Harris, E. S. Jaﬀe, H. Stein et al., “A revised European-
American classiﬁcation of lymphoid neoplasms: a proposal
from the International Lymphoma Study Group,” Blood, vol.
84, no. 5, pp. 1361–1392, 1994.
[82] J.-P. Farcet, P. Gaulard, J.-P. Marolleau et al., “Hepatosplenic
T-cell lymphoma: sinusal/sinusoidal localization of malignant
cells expressing the T-cell receptor γδ,” Blood, vol. 75, no. 11,
pp. 2213–2219, 1990.
[83] F. M. Stevens and R. M. McLoughlin, “Is coeliac disease a
potentially treatable cause of liver failure?” European Journal
of Gastroenterology and Hepatology, vol. 17, no. 10, pp. 1015–
1017, 2005.
[84] K. Kaukinen, L. Halme, P. Collin et al., “Celiac disease in
patients with severe liver disease: gluten-free diet may reverse
hepatic failure,” Gastroenterology, vol. 122, no. 4, pp. 881–888,
2002.
[85] D. Villalta, M. Crovatto, S. Stella, E. Tonutti, R. Tozzoli, and N.
Bizzaro, “False positive reactions for IgA and IgG anti-tissue
transglutaminaseantibodiesinlivercirrhosisarecommonand
method-dependent,” Clinica Chimica Acta, vol. 356, no. 1-2,
pp. 102–109, 2005.
[86] M.S´ ar dy ,M.Csik´ os,C.Geisenetal.,“Tissuetransglutaminase
ELISA positivity in autoimmune disease independent of
gluten-sensitive disease,” Clinica Chimica Acta, vol. 376, no. 1-
2, pp. 126–135, 2007.
[87] N. Bizzaro, M. Tampoia, D. Villalta et al., “Low speciﬁcity
of anti-tissue transglutaminase antibodies in patients with
primary biliary cirrhosis,” Journal of Clinical Laboratory
Analysis, vol. 20, no. 5, pp. 184–189, 2006.
[88] L. M. Luft, S. G. Barr, L. O. Martin, E. K. L. Chan, and
M. J. Fritzler, “Autoantibodies to tissue transglutaminase in
Sj¨ ogren’s syndrome and related rheumatic diseases,” Journal of
Rheumatology, vol. 30, no. 12, pp. 2613–2619, 2003.